<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">De</forename><surname>Santis</surname></persName>
						</author>
						<author>
							<persName><surname>Maria</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Von</forename><surname>Fischer</surname></persName>
						</author>
						<author>
							<persName><surname>Weikersthal</surname></persName>
						</author>
						<author>
							<persName><surname>Ludwig</surname></persName>
						</author>
						<author>
							<persName><roleName>Lerchenmüller, Christian, Zimmermann, Uwe, Bos</roleName><forename type="first">Peter</forename><forename type="middle">J</forename><surname>Goebell</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Urologische Klinik und Klinik fu ¨r Ha ¨matologie und Onkologie</orgName>
								<orgName type="institution" key="instit2">Universita ¨tsklinikum Erlangen</orgName>
								<address>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Christian</forename><surname>Eichelberg</surname></persName>
							<email>christian.eichelberg@ukr.de</email>
							<affiliation key="aff0">
								<orgName type="department">Hamburg and Caritas-St. Josef Medical Centre</orgName>
								<orgName type="institution" key="instit1">Universita ¨tsklinikum Hamburg-Eppendorf</orgName>
								<orgName type="institution" key="instit2">University of Regensburg</orgName>
								<address>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Walter</forename><forename type="middle">L</forename><surname>Vervenne</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Deventer Ziekenhuis</orgName>
								<address>
									<settlement>Deventer</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><surname>De Santis</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Centre for Oncology and Haematology</orgName>
								<orgName type="institution">Ludwig Boltzmann Institute for Applied Cancer Research</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Kaiser Franz Josef-Spital</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ludwig</forename><surname>Fischer Von Weikersthal</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Gesundheitszentrum Klinikum Amberg</orgName>
								<address>
									<settlement>Amberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Lerchenmu</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Onkologisches Zentrum Mu ¨nster</orgName>
								<address>
									<addrLine>Mu ¨nster</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uwe</forename><surname>Zimmermann</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Urologische Universita ¨tsklinik Greifswald</orgName>
								<address>
									<settlement>Greifswald</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Monique</forename><forename type="middle">M E M</forename><surname>Bos</surname></persName>
							<affiliation key="aff8">
								<orgName type="laboratory">Reinier de Graaf Gasthuis</orgName>
								<address>
									<settlement>Delft</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Freier</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Onkologische Praxis</orgName>
								<address>
									<settlement>Hildesheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Silke</forename><surname>Schirrmacher-Memmel</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Klinikum Fulda</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Staehler</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Universita ¨tsklinikum Grosshadern</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sascha</forename><surname>Pahernik</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Universita ¨tsklinikum Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maartje</forename><surname>Los</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">St. Antonius Ziekenhuis</orgName>
								<address>
									<settlement>Nieuwegein</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marcus</forename><surname>Schenck</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Urologische Universita ¨tsklinik Essen</orgName>
								<address>
									<settlement>Essen, Charite´Universita ¨tsmedizin Berlin, Berlin</settlement>
									<country>Germany, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><surname>Flo ¨rcken O , Cornelis Van Arkel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kirsten</forename><surname>Hauswald</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Slingeland Ziekenhuis q iOMEDICO AG</orgName>
								<address>
									<settlement>Doetinchem, Freiburg</settlement>
									<country>The Netherlands;, Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Indorf</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dana</forename><surname>Gottstein</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">ICRC Weyer GmbH</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maurice</forename><forename type="middle">S</forename><surname>Michel</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">University Medical Centre Mannheim</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Klinik fu ¨r Urologie</orgName>
								<orgName type="institution">Universita ¨t Regensburg, am Caritas-Krankenhaus St. Josef</orgName>
								<address>
									<addrLine>Landshuter Straße 65</addrLine>
									<postCode>93053</postCode>
									<settlement>Regensburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="laboratory">Treatment of Metastatic Renal Cell Cancer. Eur Urol (2015)</orgName>
								<address>
									<addrLine>http://dx.doi.org/10.1016/j.eururo</addrLine>
									<postCode>2015.04.017</postCode>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">71A8ECEDA73F91432EA61A33C71E804C</idno>
					<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
					<note type="submission">Accepted April 13, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Renal cell carcinoma Sequential therapy Sorafenib Sunitinib</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Silke et al.. (2015) SWITCH : A randomised, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-sunitinib versus Sunitinib-sorafenib in the treatment of metastatic renal cell cancer.</s><s>European Urology.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Treatment of metastatic renal cell carcinoma (mRCC) has greatly improved over the past decade with the introduction of targeted therapies acting on vascular endothelial growth factor receptor (VEGFR) or mammalian target of rapamycin (mTOR) <ref type="bibr" target="#b18">[1]</ref>.</s><s>However, as most patients experience disease progression during treatment with targeted therapy, sequential treatment with different agents has become standard practice <ref type="bibr" target="#b19">[2,</ref><ref type="bibr" target="#b20">3]</ref>.</s><s>Choosing the sequence of agents to optimise outcomes remains a key clinical challenge <ref type="bibr" target="#b20">[3,</ref><ref type="bibr" target="#b21">4]</ref>.</s><s>Sorafenib and sunitinib are multikinase inhibitors with overlapping but not identical kinase inhibition profiles.</s><s>They target VEGFR 1-3, platelet-derived growth factor receptor, and c-Kit <ref type="bibr" target="#b22">[5,</ref><ref type="bibr" target="#b23">6]</ref>; sorafenib also targets BRAF and RET <ref type="bibr" target="#b23">[6]</ref>.</s><s>Both are approved for the treatment of mRCC in first-line (sunitinib) and cytokine-unsuitable (sorafenib) settings; sorafenib has shown efficacy in multiple treatment lines <ref type="bibr" target="#b19">[2,</ref><ref type="bibr" target="#b24">[7]</ref><ref type="bibr" target="#b25">[8]</ref><ref type="bibr" target="#b26">[9]</ref><ref type="bibr" target="#b27">[10]</ref><ref type="bibr" target="#b28">[11]</ref>.</s></p><p><s>In retrospective studies, sequential use of sorafenib and sunitinib in mRCC was well tolerated and provided additional clinical benefit beyond the use of either agent alone; these retrospective studies suggested that outcomes could be better with sorafenib followed by sunitinib (So-Su) compared with sunitinib followed by sorafenib (Su-So) <ref type="bibr" target="#b20">[3,</ref><ref type="bibr" target="#b29">[12]</ref><ref type="bibr" target="#b30">[13]</ref><ref type="bibr" target="#b31">[14]</ref><ref type="bibr" target="#b32">[15]</ref><ref type="bibr" target="#b33">[16]</ref>.</s><s>The largest retrospective analysis at the time when the present study was designed (n = 189) revealed a numerically longer progression-free survival (PFS) for So-Su than for Su-So (17.2 vs 11.7 mo) <ref type="bibr" target="#b32">[15,</ref><ref type="bibr" target="#b34">17]</ref>.</s><s>SWITCH was the first prospective, randomised, phase 3 study to test the hypothesis that sequential therapy with So-Su is superior to Su-So in prolonging total PFS (defined as time from randomisation to confirmed progression or death during second-line therapy) in advanced/metastatic RCC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.</head><p><s>Patients and methods (MSKCC) risk score <ref type="bibr" target="#b35">[18]</ref>; and adequate bone marrow, liver, and renal function.</s><s>Exclusion criteria included unstable or severe cardiac disease;</s></p><p><s>active, clinically serious infections; and symptomatic metastatic brain tumours.</s><s>All patients gave written informed consent.</s><s>The study complied with local legal and regulatory requirements and the Declaration of Helsinki/Good Clinical Practice guidelines.</s></p><p><s>Patients were randomised to sorafenib 400 mg twice daily followed by sunitinib 50 mg once daily (4 wk on, 2 wk off) (So-Su) or vice versa (Su-So).</s><s>The treatment cycle length was 6 wk for both sorafenib and sunitinib.</s><s>Dose modifications to manage adverse events (AEs) were permitted at the discretion of the investigator; the protocol included recommendations on when and how to implement dose reductions, interruptions, and permanent discontinuations.</s><s>The sorafenib dose could be reduced to 400 mg once daily and then 400 mg every other day.</s></p><p><s>The sunitinib dose could be reduced to 37.5 mg once daily and then</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Study endpoints and assessments</head><p><s>Supplementary Table <ref type="table" target="#tab_4">1</ref> summarises the key endpoints.</s><s>The primary endpoint was total PFS (time from randomisation to confirmed progression or death during second-line therapy).</s><s>First-line events</s></p><p><s>Results and limitations: In total, 365 patients were randomised (So-Su, n = 182; Su-So, n = 183).</s><s>There was no significant difference in total PFS between So-Su and Su-So (median 12.5 vs 14.9 mo; hazard ratio [HR] 1.01; 90% confidence interval [CI] 0.81-1.27;</s><s>p = 0.5 for superiority).</s><s>OS was similar for So-Su and Su-So (median 31.5 and 30.2 mo; HR 1.00, 90% CI 0.77-1.30;</s><s>p = 0.5 for superiority).</s><s>More So-Su patients than Su-So patients reached protocol-defined second-line therapy (57% vs 42%).</s><s>Overall, adverse event rates were generally similar between the treatment arms.</s><s>The most frequent any-grade treatment-emergent first-line adverse events were diarrhoea (54%) and hand-foot skin reaction (39%) for sorafenib; and diarrhoea (40%) and fatigue (40%) for sunitinib.</s><s>Conclusions: Total PFS was not superior with So-Su versus Su-So.</s><s>These results demonstrate that sorafenib followed by sunitinib and vice versa provide similar clinical benefit in mRCC.</s><s>Patient summary: We investigated if total progression-free survival (PFS) is improved in patients with advanced/metastatic kidney cancer who are treated with sorafenib and then with sunitinib (So-Su), compared with sunitinib and then sorafenib (Su-So).</s><s>We found that total PFS was not improved with So-Su compared with Su-So, but both treatment options were similarly effective in patients with advanced/metastatic kidney cancer.</s><s>analysis evaluated updated OS, with a data cutoff of January 14, 2014, using 172 events.</s><s>No corrections were made for multiple hypothesis testing.</s><s>Safety was assessed in all patients receiving at least one dose of study treatment and was summarised using descriptive statistics.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Patients</head><p><s>From February 2009 to December 2011, 365 patients were randomised (182 to So-Su; 183 to Su-So) at 72 centres in Germany, Austria, and the Netherlands (Fig. <ref type="figure" target="#fig_2">1</ref>).</s><s>Patient demographics and baseline characteristics were well balanced between the treatment groups (Table <ref type="table" target="#tab_4">1</ref>).</s><s>Although the study protocol mandated that patients should not have received prior treatment and should be unsuitable for cytokines, seven patients had prior interferon-a and four patients had prior interleukin-2.</s><s>These patients were included in the analyses under the intention-to-treat principle.</s><s>At data cutoff for all analyses (August 15, 2013), the mean follow-up (from last treatment to end of follow-up) was 10.3 mo.</s><s>Overall, 353 (97%) patients received first-line treatment and 179 (49%) patients received second-line treatment.</s><s>More patients reached protocol-defined second-line therapy in the So-Su arm (n = 103, 57%) than in the Su-So arm (n = 76, 42%; p &lt; 0.01; Fig. <ref type="figure" target="#fig_2">1</ref>).</s><s>When the 13 So-Su and 24 Su-So patients receiving documented, non-protocol-defined second-line therapy were included, the difference was no longer statistically significant (n = 116 [64%] vs n = 100 [55%]; p = 0.09).</s><s>Of the 103 So-Su patients and 76 Su-So patients who received perprotocol first-and second-line therapy, 52 and 36 patients, respectively, went on to receive further treatment.</s><s>Subsequent therapy for patients who discontinued the study after first-line therapy and for those who received both firstand second-line therapy is detailed in Supplementary Table <ref type="table" target="#tab_7">3</ref>, and typically included mTOR inhibitors (everolimus and temsirolimus) and VEGF(R) inhibitors (bevacizumab/ interferon, pazopanib, sunitinib, sorafenib).</s><s>Some patients received second-line sorafenib or sunitinib outside of the study protocol, mostly because of a treatment break longer than the protocol-specified 28 d.</s></p><p><s>In both groups, the most common reason for stopping first-line therapy was disease progression.</s><s>The most frequent reasons for not initiating protocol-defined second-line treatment after stopping first-line treatment were death (So-Su n = 16 [8.8%];</s><s>Su-So n = 19 [10%]) and adverse events (So-Su n = 8 [4.4%]; Su-So n = 17 [9.3%];</s><s>Fig. <ref type="figure" target="#fig_2">1</ref>).</s><s>Demographic and baseline characteristics were generally similar between patients who received first-line therapy only and those who received both first-and second-line therapy, although patients not progressing to second-line therapy typically had a less favourable MSKCC score and ECOG PS and more previous treatment; in addition, fewer patients had undergone nephrectomy and more had non-clear-cell histology (Supplementary Table <ref type="table">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Efficacy</head><p><s>At data cutoff (August 15, 2013), the primary objective was not met: So-Su was not superior to Su-So in terms of PFS (median 12.5 vs 14.9 mo; HR 1.01, 90% CI 0.81-1.27;</s><s>p = 0.5 for superiority; Fig. <ref type="figure">2A</ref>).</s><s>OS was similar in both arms (median 31.5 mo for So-Su and 30.2 mo for Su-So; HR 1.00, 90% CI 0.77-1.30;</s><s>p = 0.5 for superiority; Fig. <ref type="figure">2B</ref>).</s><s>Median follow-up for patients without an OS event was 1.4 mo for So-Su and 3.0 mo for Su-So.</s><s>Median first-line PFS was also similar between the two groups (5.9 mo for So-Su vs 8.5 mo for Su-So; HR 1.19, 90% CI 0.97-1.47;</s><s>p = 0.9 for superiority; Fig. <ref type="figure">3a</ref>).</s><s>Median second-line PFS was longer for So-Su than for Su-So (5.4 vs 2.8 mo; HR 0.55, 90% CI 0.41-0.74;</s><s>p &lt; 0.001 for superiority; Fig. <ref type="figure">3B</ref>).</s><s>ORR and DCR were similar during first-line treatment with sorafenib and sunitinib.</s><s>During second-line treatment, ORR and DCR were higher for sunitinib than for sorafenib (p = 0.03 for DCR; Table <ref type="table" target="#tab_6">2</ref>).</s><s>Median time to first-line treatment failure (6.0 vs 9.0 mo; HR 1.15, 90% CI 0.93-1.42;</s><s>p = 0.9 for superiority) and median total TTP (15.2 vs 17.2 mo; HR 1.01, 90% CI 0.79-1.30;</s><s>p = 0.5 for superiority) were comparable between the So-Su and Su-So groups.</s><s>Updated survival analysis (data cutoff January 14, 2014) revealed median OS of 30.0 mo for So-Su and 27.4 mo for Su-So (HR 0.99, 90% CI 0.77-1.27;</s><s>p = 0.5 for superiority; Supplementary Fig. <ref type="figure" target="#fig_2">1</ref>) <ref type="bibr" target="#b36">[19]</ref>.</s></p><p><s>Efficacy findings in the per-protocol population were generally consistent with those in the ITT population (data not shown), except for the interim OS analysis <ref type="bibr">(31.5</ref>   p = 0.6 for superiority).</s><s>In the updated analysis, median OS in the per-protocol population (31.5 mo for So-Su vs 30.2 mo for Su-So; HR 1.06, 90% CI 0.81-1.40;</s><s>p = 0.6 for superiority) was again consistent with that in the ITT population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Safety</head><p><s>The safety population included 177 So-Su patients and 176 Su-So patients who received at least one dose of firstline study treatment.</s><s>The safety results are summarised in Table <ref type="table" target="#tab_7">3</ref>.</s><s>The mean duration of first-line therapy was not significantly different between sorafenib and sunitinib (log rank test p = 0.1).</s><s>During second-line treatment, the mean duration of therapy was shorter for sorafenib (Su-So arm) Cardiac safety parameters (LVEF and NT-proBNP) were similar between the groups at all three assessment visits (Supplementary Table <ref type="table">5</ref>).</s><s>No other significant differences in OS were observed between subgroups (Fig. <ref type="figure">4</ref>).</s><s>In the updated OS analysis (cutoff January 14, 2014), the only significant difference between post hoc subgroups was that patients aged &gt;65 yr experienced a greater benefit with So-Su than Su-So (median OS 31.5 vs 19.8 mo; p = 0.04; Supplementary Table <ref type="table">6</ref>) <ref type="bibr" target="#b36">[19]</ref>.</s><s>To explore possible reasons for the apparent improved OS in older patients who received So-Su compared with Su-So, the number of patients aged 65 or &gt;65 yr who received each treatment line, the duration of treatment for each line, and the incidence of grade 3/4 AEs were determined (Supplementary Table <ref type="table">7</ref>).</s><s>In patients aged &gt;65 yr, the mean duration of first-line treatment was similar in each treatment arm (35.7 wk So-Su vs 39.8 wk Su-So, p = 0.6); the mean duration of second-line treatment was 36.0 wk with So-Su and 12.9 wk with Su-So (p &lt; 0.0001).</s><s>Rates of grade 3/4 AEs tended to be higher with sunitinib than with sorafenib in both the first and second lines of treatment (first line, Su-So 67% vs So-Su 55%, p = 0.1; second line, So-Su 55% vs Su-So 26%, p = 0.02).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>Initiated in 2008, SWITCH was the first prospective, randomised phase 3 study of sequential tyrosine kinase inhibitor (TKI) therapy (So-Su vs Su-So) for advanced/ metastatic RCC.</s><s>Both drugs provided overall clinical benefit, regardless of treatment sequence.</s><s>The primary objective was not met: total PFS was not superior with So-Su versus Su-So (median 12.5 vs 14.9 mo; HR 1.01).</s><s>OS was similar in both arms: median 31.5 and 30.2 months with So-Su and Su-So, respectively (HR 1.00).</s><s>Likewise, total TTP was comparable between So-Su and Su-So (15.2 and 17.2 mo; HR 1.01).</s><s>In both arms, total TTP was approximately 2.5 mo longer than total PFS.</s><s>This may have  <ref type="formula">17</ref>) 57 ( <ref type="formula">16</ref>) methodological reasons as, unlike PFS, calculation of TTP did not include deaths.</s><s>Further prospective randomised studies investigating the optimal sequencing of targeted agents are ongoing, e.g. the SWITCH-II study (NCT01613846) assessing sorafenib and pazopanib in sequence <ref type="bibr" target="#b37">[20]</ref>.</s><s>First-line PFS for each agent in SWITCH (sorafenib 5.9 mo; sunitinib 8.5 mo) was within the previously reported range (4.4-11.6 mo for sorafenib and 5.1-13.1 mo for sunitinib) <ref type="bibr" target="#b27">[10,</ref><ref type="bibr" target="#b32">15,</ref><ref type="bibr" target="#b33">16,</ref><ref type="bibr" target="#b38">[21]</ref><ref type="bibr" target="#b39">[22]</ref><ref type="bibr" target="#b40">[23]</ref>.</s><s>Second-line PFS with sorafenib following first-line sunitinib in the phase 3 INTORSECT and AXIS studies (3.9 and 3.4 mo, respectively) <ref type="bibr" target="#b25">[8,</ref><ref type="bibr" target="#b28">11]</ref> was also consistent with that seen in SWITCH (2.8 mo).</s><s>Both first-and second-line PFS in SWITCH were consistent with results from the largest retrospective study reported to date (n = 2106 across multiple centres) <ref type="bibr" target="#b41">[24]</ref>.</s><s>In that study, Alimohamed et al reported first-line PFS of 7.3 mo for sorafenib (n = 412) and 7.2 mo for sunitinib (n = 1542), and second-line PFS of 3.6 mo for sorafenib following sunitinib (n = 257), and 5.2 mo for sunitinib following sorafenib (n = 152) <ref type="bibr" target="#b41">[24]</ref>.</s><s>In SWITCH, second-line PFS for sunitinib following sorafenib was 5.4 mo.</s><s>In their large retrospective study, Alimohamed et al concluded that the sequence in which targeted therapies are used does not substantially affect clinical outcome <ref type="bibr" target="#b41">[24]</ref>.</s><s>While our PFS findings confirm this observation, response rates appeared to differ for the treatment sequences.</s><s>ORR (31% and 29%) and DCR (69% and 64%) were similar for first-line sorafenib and sunitinib, respectively.</s><s>However, compared with patients receiving Su-So, those receiving So-Su had greater second-line ORR (17% vs 6.6%) and DCR (49% vs 32%).</s><s>The clinical relevance of these observations remains unclear, particularly in the context of our PFS findings.</s></p><formula xml:id="formula_0">ECOG</formula><p><s>To the best of our knowledge, no other phase 3 studies of sequential TKI therapy in RCC have been reported.</s><s>Findings of a phase 2 study (RECORD-3) investigating sequential everolimus followed by sunitinib (Ev-Su) compared with</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Median (90% CI) PFS, n mo</head><p><s>So-Su 182 5.9 (5.5-7.</s><s>sunitinib followed by everolimus (Su-Ev) were recently published <ref type="bibr" target="#b42">[25]</ref>.</s><s>Median total PFS was 21.1 mo for Ev-Su and 25.8 mo for Su-Ev (HR 1.3, 95% CI 0.9-1.7)</s><s>and OS was 22.4 mo for Ev-Su and 32.0 mo for Su-Ev (HR 1.2, 95% CI 0.9-1.6).</s><s>Notably, 207 patients (44%) overall in RECORD-3 received per-protocol second-line treatment, similar to the proportion of patients who received secondline treatment in our study (179 patients, 49%).</s></p><p><s>One key challenge in managing mRCC is that only approximately half of patients proceed from first-line to second-line treatment.</s><s>In the present study, more patients reached second-line therapy on protocol in the So-Su compared with the Su-So arm (57% vs 42%; p &lt; 0.01).</s><s>This is consistent with data from other studies suggesting that patients receiving sorafenib early in the treatment sequence are more likely to receive subsequent therapies than those receiving first-line sunitinib (34-38% for sorafenib vs 16-18% for sunitinib) <ref type="bibr" target="#b43">[26,</ref><ref type="bibr" target="#b44">27]</ref>.</s><s>The reasons for this difference are not clear.</s><s>Notably, patients in our study who did not progress to second-line therapy happened to have more advanced disease (less favourable MSKCC score and ECOG PS; more prior treatment) or poorer prognosis (fewer patients had undergone nephrectomy; more with nonclear-cell histologies) than those who did progress to second-line therapy.</s><s>Furthermore, differences in the firstline AE profiles may impact patients' willingness or ability    to continue to second-line treatment, as has been shown elsewhere <ref type="bibr" target="#b45">[28,</ref><ref type="bibr" target="#b46">29]</ref>.</s><s>The most common reasons cited by investigators for not continuing to second-line treatment in SWITCH in the So-Su versus Su-So arms, respectively, were death (16% vs 19%), AEs (8% versus 17%), and withdrawn consent (9% vs 13%).</s><s>Safety profiles differed between sorafenib and sunitinib, but were generally as expected and consistent with previous reports for these agents in patients with mRCC <ref type="bibr" target="#b47">[30,</ref><ref type="bibr" target="#b48">31]</ref>.</s><s>AEs were generally less frequent during second-line than first-line therapy.</s><s>Although the precise reasons are not known, this observation is consistent with previous data showing that AEs tend to occur early in the course of TKI therapy <ref type="bibr" target="#b52">[32,</ref><ref type="bibr" target="#b53">33]</ref>, and suggests possible cross-tolerance and adaptation to TKI treatment.</s><s>Prospective assessment of cardiac safety (LVEF and NT-proBNP values) was included in the protocol following previous reports of cardiotoxicity and reduced LVEF, particularly with sunitinib <ref type="bibr" target="#b47">[30,</ref><ref type="bibr" target="#b54">[34]</ref><ref type="bibr" target="#b55">[35]</ref><ref type="bibr" target="#b56">[36]</ref><ref type="bibr" target="#b57">[37]</ref><ref type="bibr" target="#b58">[38]</ref>.</s><s>For example, a meta-analysis found a higher risk of all-grade and high-grade congestive heart failure, mainly defined as declines in LVEF, in sunitinib-treated compared with placebo-treated renal and nonrenal cancer patients <ref type="bibr" target="#b58">[38]</ref>.</s><s>In addition to monitoring and managing hypertension, which may be associated with cardiac events in patients receiving TKIs <ref type="bibr" target="#b55">[35,</ref><ref type="bibr" target="#b57">37]</ref>, NT-proBNP represents a more convenient and potentially more reliable early marker of cardiac damage than LVEF <ref type="bibr" target="#b59">[39,</ref><ref type="bibr" target="#b60">40]</ref>.</s><s>Results for LVEF and NT-proBNP monitoring in SWITCH indicated that neither sorafenib nor sunitinib significantly affected cardiac safety.</s><s>This is consistent with findings from an ongoing phase 3, randomised, placebo-controlled study of adjuvant sorafenib or sunitinib in patients with resected, nonmetastatic RCC at high risk of recurrence (NCT00326898).</s><s>In that study, LVEF declines were negligible, occurring in only 2.3%, 1.8%, and 1.0% of patients receiving sunitinib, sorafenib, and placebo, respectively <ref type="bibr" target="#b62">[41]</ref>.</s><s>Subgroup analyses for age, sex, risk of recurrence, and baseline performance status (ECOG PS 0 vs 1) revealed no differences between So-Su and Su-So in terms of total PFS, OS, or first-line PFS apart from statistically significant differences in OS according to age, with the results favouring So-Su in patients aged &gt;65 yr (Fig. <ref type="figure">4B</ref> and Supplementary Table <ref type="table">6</ref>) <ref type="bibr" target="#b36">[19]</ref>.</s><s>The reasons for this difference are unclear.</s><s>The study design did not include patient stratification according to age, and our observations should be considered as hypothesis-generating only.</s><s>Nonetheless, it is interesting that sorafenib appeared to be somewhat better tolerated than sunitinib in elderly patients in our study.</s><s>Indeed, age was included in our subgroup analyses as previous analyses suggested that sorafenib is effective and well tolerated particularly in elderly patients <ref type="bibr" target="#b53">[33,</ref><ref type="bibr" target="#b63">[42]</ref><ref type="bibr" target="#b64">[43]</ref><ref type="bibr" target="#b65">[44]</ref>.</s></p><p><s>The study has a number of limitations to be considered when interpreting the results.</s><s>The study was open-label rather than double-blind, introducing a potential for investigator bias; however, the protocol mandated that confirmed radiologic progression was required to stop treatment on the grounds of disease progression, which reduced this potential for bias.</s><s>The findings for second-line PFS may not be robust because there were low numbers of patients/ events; fewer patients received on-study second-line treatment with sunitinib compared with sorafenib; and only selected subsets of patients were able to receive secondline treatment.</s><s>The results for second-line therapy should therefore be interpreted with caution.</s><s>OS could have been confounded by subsequent treatments received after patients completed per-protocol therapy.</s><s>Limited prospective sequential data were available at the time at which the study was designed, so it was not possible to estimate the impact that an imbalance in discontinuation could have on the study findings, particularly in terms of total PFS and second-line PFS.</s><s>The different safety profiles of sorafenib and sunitinib may have contributed to differences in first-line therapy discontinuation, and thus affected first-line PFS and total PFS.</s><s>In sequential studies, the decision to end first-line treatment can potentially be influenced by investigator knowledge that a second-line treatment is readily available.</s><s>In SWITCH, however, confirmed radiologic progression was required to proceed to second-line treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p><s>SWITCH is the first prospective, randomised, phase 3 study of sequential TKI therapy (So-Su vs Su-So) for advanced/ metastatic RCC; 49% of patients received per-protocol second-line therapy.</s><s>The primary endpoint of total PFS was not met, but the results did confirm the clinical benefit of sequential treatment, with median OS of approximately 30 mo.</s><s>Further prospective randomised studies investigating the optimal sequencing of targeted agents are ongoing.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>25 mg once daily.</s><s>Randomisation was stratified by MSKCC score (favourable vs intermediate).</s><s>Centralised randomisation via fax was coordinated by iOMEDICO AG (Germany).</s><s>The randomisation list was generated by ICRC Weyer GmbH using an SAS program.</s><s>The person who generated the randomisation list was not involved in the study project management, monitoring, or data management.</s><s>First-line treatment in both arms continued until disease progression according to RECIST or intolerable toxicity (after unsuccessful dose reduction/interruption).</s><s>There was a treatment-free crossover period of 1-4 wk after first-line treatment to avoid additive toxicity.</s><s>Patients who discontinued first-line treatment because of toxicity began second-line treatment only after nonhaematological toxicity had resolved to grade 1 and haematological toxicity to grade 2. Patients who refused further first-line treatment because of toxicity could begin second-line treatment if they consented and were in general compliance with the study protocol.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>event), which included patients who received off-protocol second-line therapy instead of per-protocol second-line therapy.</s><s>It also included patients who ultimately received the correct sequence but not per protocol; for example, a patient who received second-line sorafenib &gt;4 wk after stopping first-line sunitinib would be recorded as receiving off-protocol second-line therapy.</s><s>Time-to-event endpoints were assessed using a one-sided log-rank test with a significance level of a = 0.05.</s><s>The log-rank test is symmetric: the calculated p values are the same whether the test is one-or two-sided, although the significance level for the two-sided test would be halved to 0.025.</s><s>For PFS, OS, TTP, and time to first-line treatment failure, hazard ratios (HRs) and two-sided 90% confidence intervals (CIs) were derived from a Cox proportional hazard model.</s><s>ORR and DCR were assessed using Fisher's exact test.</s><s>Post hoc analysis assessed differences between treatment arms for total PFS, OS, and first-line PFS in subgroups for age (&gt;65 vs 65 yr), sex, MSKCC score (favourable vs intermediate), and ECOG PS (0 vs 1).</s><s>A further post hoc</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 1 -</head><label>1</label><figDesc><div><p><s>Fig. 1 -Patient disposition.</s><s>a Reasons for stopping treatment as reported by the investigator.</s><s>b Other reasons included investigator decision, lost to follow-up, and noncompliance.</s><s>So = sorafenib; Su = sunitinib.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>than for sunitinib (So-Su arm; log rank test p &lt; 0.001).</s><s>The mean (AE standard deviation) treatment break between firstand second-line therapy (excluding the regular 2-wk interval after sunitinib) was 21 AE 16 d for So-Su and 17 AE 14 d for Su-So (p = 0.1).</s><s>The most common treatment-emergent AEs were diarrhoea, hand-foot skin reaction, hypertension, and fatigue for first-line sorafenib, and diarrhoea, fatigue, hypertension, and nausea for first-line sunitinib.</s><s>Withdrawal because of AEs during first-line treatment was significantly more frequent in the Su-So arm (n = 52, 30%) than in the So-Su arm (n = 33, 19%; p = 0.02).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head></head><label></label><figDesc><div><p><s>PS = Eastern Cooperative Oncology Group performance status; MSKCC = Memorial Sloan Kettering Cancer Center; So = sorafenib; Su = sunitinib.</s><s>a Based on central assessment post-randomisation.</s><s>Imbalance in MSKCC risk score distribution occurred because of incorrect site entries at randomisation.</s><s>b Presented for the safety population, So-Su n = 177, Su-So n = 176, total n = 353.</s><s>c Some patients received more than one previous cancer treatment.</s><s>For two of the patients assigned to the Su-So group, the information was missing.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Fig. 3 -Fig. 2 -</head><label>32</label><figDesc><div><p><s>Fig.3-Kaplan-Meier plots of (A) first-line progression-free survival and (B) second-line progression-free survival (intention-to-treat population).</s><s>CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; So = sorafenib; Su = sunitinib.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc><div><p><s>; Su = sunitinib.</s><s>a Included only patients who received at least one dose of study drug in the respective treatment line.</s><s>Response evaluation was based on investigator assessment.</s><s>b Objective response rate = complete response + partial response.</s><s>c Disease control rate = complete response + partial response + stable disease !8 wk.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head></head><label></label><figDesc><div><p><s>deviation; So = sorafenib; Su = sunitinib; TEAE = treatment-emergent adverse event.</s><s>a n = 176.</s><s>b p = 0.1.</s><s>c p &lt; 0.001.</s><s>d n = 74.</s><s>e p = 0.02.</s><s>f Any-grade AE in &gt;20% of patients in either arm, or grade 3/4 AEs in &gt;3% of patients in either arm.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>Trial registration: ClinicalTrials.gov</s><s>identifier NCT00732914, www.clinicaltrials.gov</s><s># 2015 European Association of Urology.</s><s>Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).</s></p></div></figDesc><table><row><cell cols="2">were used for patients who did not switch to per-protocol second-line</cell></row><row><cell cols="2">therapy. Patients without tumour progression or death were censored at</cell></row><row><cell cols="2">their last date for tumour evaluation. Secondary endpoints included</cell></row><row><cell cols="2">overall survival (OS; time from randomisation to time of death from</cell></row><row><cell cols="2">any cause); first-line PFS (time from randomisation to confirmed</cell></row><row><cell cols="2">progression or death during first-line therapy); second-line PFS (time</cell></row><row><cell cols="2">from first day of second-line therapy to confirmed progression or death</cell></row><row><cell cols="2">during second-line therapy); objective response rate (ORR; complete or</cell></row><row><cell cols="2">partial responses) and disease control rate (DCR; complete or partial</cell></row><row><cell cols="2">responses or stable disease for !8 wk) during first-line and second-line</cell></row><row><cell cols="2">therapy; total time to progression (TTP; time from randomisation</cell></row><row><cell cols="2">to confirmed progression during second-line therapy); and time to</cell></row><row><cell cols="2">first-line treatment failure (time from randomisation to progression,</cell></row><row><cell cols="2">death, or discontinuation due to toxicity). The tumour response was</cell></row><row><cell cols="2">assessed according to RECIST by CT/MRI after every second cycle</cell></row><row><cell cols="2">(ie, every 12 wk). Responses were confirmed by repeat CT/MRI at least</cell></row><row><cell cols="2">4 wk after being first recorded. Crossover from first-line to second-line</cell></row><row><cell cols="2">treatment required a CT scan, which was the baseline scan for second-</cell></row><row><cell cols="2">line treatment. Safety was assessed for each treatment line using</cell></row><row><cell cols="2">National Cancer Institute Common Terminology Criteria for Adverse</cell></row><row><cell cols="2">Events v3.0 at 0, 3, 6, 9, and 12 wk, and then every 6 wk and at treatment</cell></row><row><cell cols="2">end. Cardiotoxicity was assessed by monitoring left ventricular ejection</cell></row><row><cell cols="2">fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP)</cell></row><row><cell cols="2">levels. LVEF was determined by echocardiography at baseline, then</cell></row><row><cell cols="2">every 12 wk, on the last day of first-line treatment, and treatment</cell></row><row><cell cols="2">end. NT-proBNP was measured at baseline, on day 1 of each cycle, on</cell></row><row><cell cols="2">the last day of first-line treatment, and at treatment end.</cell></row><row><cell>2.3.</cell><cell>Statistical analysis</cell></row><row><cell cols="2">SWITCH was planned as a noninferiority study based on data available in</cell></row><row><cell cols="2">2008, with a planned sample size of 540 patients to observe 381 events.</cell></row><row><cell cols="2">However, with the emergence of considerable retrospective data</cell></row><row><cell cols="2">suggesting that So-Su might provide longer combined PFS and OS than</cell></row><row><cell cols="2">Su-So (particularly the large retrospective study by Porta et al [15]),</cell></row><row><cell cols="2">SWITCH was amended in June 2010 to a superiority design; 138 patients</cell></row><row><cell cols="2">had already been randomised. The sample size for the superiority design</cell></row><row><cell cols="2">was originally based on the following assumptions: overall PFS of</cell></row><row><cell cols="2">17.2 versus 11.7 mo for So-Su versus Su-So [17]; accrual period of 36 mo;</cell></row><row><cell cols="2">total treatment duration of 54 mo; 231 events; and 10% of patients not</cell></row><row><cell cols="2">evaluable for statistical analysis. A sample size of 346 would provide 90%</cell></row><row><cell cols="2">power to show a 47% increase in total PFS. A protocol amendment in</cell></row><row><cell cols="2">August 2013, after all planned patients had been randomised, reduced</cell></row><row><cell cols="2">the power from 90% to 85%, and thus reduced the required sample size to</cell></row><row><cell cols="2">272 patients to show 194 events. This amendment was made because</cell></row><row><cell cols="2">of a slower than expected rate of events.</cell></row><row><cell cols="2">Efficacy was assessed in the intention-to-treat (ITT) population,</cell></row></table><note><p><s>which included all randomised patients; for ORR and DCR, only patients who received at least one dose of study drug in the respective treatment line were included.Missing values were not imputed.For time-to-event analysis, missing values were censored.Details of event handling with respect to the primary endpoint are given in Supplementary Table2.</s><s>In particular, patients were censored if they received unauthorised cancer treatment (without progressive disease or other status counted as an</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 1 -</head><label>1</label><figDesc><div><p><s>Patient demographics and baseline characteristics (intention-to-treat population)</s></p></div></figDesc><table><row><cell>Variable</cell><cell>So-Su</cell><cell>Su-So</cell><cell>Total</cell></row><row><cell></cell><cell>(n = 182)</cell><cell>(n = 183)</cell><cell>(n = 365)</cell></row><row><cell>Median age, yr (range)</cell><cell>64 (39-84)</cell><cell>65 (40-83)</cell><cell>65 (39-84)</cell></row><row><cell>Sex, n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>43 (24)</cell><cell>48 (26)</cell><cell>91 (25)</cell></row><row><cell>Male</cell><cell>139 (76)</cell><cell>135 (74)</cell><cell>274 (75)</cell></row><row><cell>Clear cell histology, n (%)</cell><cell>164 (90)</cell><cell>154 (84)</cell><cell>318 (87)</cell></row><row><cell>Nephrectomy</cell><cell>167 (92)</cell><cell>168 (92)</cell><cell>335 (92)</cell></row><row><cell>(total or partial), n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>MSKCC risk score a , n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>High</cell><cell>1 (0.5)</cell><cell>1 (0.5)</cell><cell>2 (0.5)</cell></row><row><cell>Intermediate</cell><cell>108 (59)</cell><cell>94 (51)</cell><cell>202 (55)</cell></row><row><cell>Favourable</cell><cell>71 (39)</cell><cell>82 (45)</cell><cell>153 (42)</cell></row><row><cell>Unknown</cell><cell>2 (1.1)</cell><cell>4 (2.2)</cell><cell>6 (1.6)</cell></row><row><cell>Missing</cell><cell>0 (0)</cell><cell>2 (1.1)</cell><cell>2 (0.5)</cell></row><row><cell>ECOG PS, b n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>116 (66)</cell><cell>106 (60)</cell><cell>222 (63)</cell></row><row><cell>1</cell><cell>55 (31)</cell><cell>66 (38)</cell><cell>121 (34)</cell></row><row><cell>2</cell><cell>0 (0)</cell><cell>1 (0.6)</cell><cell>1 (0.3)</cell></row><row><cell>Missing</cell><cell>6 (3.4)</cell><cell>3 (1.7)</cell><cell>9 (2.5)</cell></row><row><cell>Metastatic sites, b n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Lung</cell><cell>139 (79)</cell><cell>126 (72)</cell><cell>265 (75)</cell></row><row><cell>Lymph nodes</cell><cell>85 (48)</cell><cell>71 (40)</cell><cell>156 (44)</cell></row><row><cell>Liver</cell><cell>36 (20)</cell><cell>42 (24)</cell><cell>78 (22)</cell></row><row><cell>Bone</cell><cell>22 (12)</cell><cell>30 (17)</cell><cell>52 (15)</cell></row><row><cell>Brain</cell><cell>6 (3.4)</cell><cell>4 (2.3)</cell><cell>10 (2.8)</cell></row><row><cell cols="2">Number of metastatic sites, b n (%)</cell><cell></cell><cell></cell></row><row><cell>1</cell><cell>38 (21)</cell><cell>51 (29)</cell><cell>89 (25)</cell></row><row><cell>2</cell><cell>68 (38)</cell><cell>59 (34)</cell><cell>127 (36)</cell></row><row><cell>3</cell><cell>51 (29)</cell><cell>36 (20)</cell><cell>87 (25)</cell></row><row><cell>!4</cell><cell>19 (11)</cell><cell>28 (16)</cell><cell>47 (13)</cell></row><row><cell cols="2">Previous cancer therapies, c n (%)</cell><cell></cell><cell></cell></row><row><cell>Interferon-a</cell><cell>2 (1.1)</cell><cell>5 (2.7)</cell><cell>7 (1.9)</cell></row><row><cell>Interleukin-2</cell><cell>1 (0.5)</cell><cell>3 (1.6)</cell><cell>4 (1.1)</cell></row><row><cell>Other</cell><cell>13 (7.1)</cell><cell>13 (7.1)</cell><cell>26 (7.1)</cell></row><row><cell>Radiotherapy</cell><cell>16 (8.8)</cell><cell>23 (13)</cell><cell>39 (11)</cell></row><row><cell>Total</cell><cell>26 (14)</cell><cell>31 (</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 2 -</head><label>2</label><figDesc><div><p><s>Best overall tumour response and disease control rate (modified intention-to-treat population) a</s></p></div></figDesc><table><row><cell>Tumour response, n (%)</cell><cell></cell><cell>First-line therapy</cell><cell></cell><cell></cell><cell>Second-line therapy</cell></row><row><cell></cell><cell>So-Su</cell><cell>Su-So</cell><cell>p value</cell><cell>So-Su</cell><cell>Su-So</cell><cell>p value</cell></row><row><cell></cell><cell>(n = 177)</cell><cell>(n = 176)</cell><cell></cell><cell>(n = 103)</cell><cell>(n = 76)</cell></row><row><cell>Complete response</cell><cell>5 (2.8)</cell><cell>6 (3.4)</cell><cell></cell><cell>1 (1.0)</cell><cell>1 (1.3)</cell></row><row><cell>Partial response</cell><cell>50 (28)</cell><cell>45 (26)</cell><cell></cell><cell>17 (17)</cell><cell>4 (5.3)</cell></row><row><cell>Stable disease</cell><cell>68 (38)</cell><cell>61 (35)</cell><cell></cell><cell>32 (31)</cell><cell>19 (25)</cell></row><row><cell>Objective response rate b</cell><cell>55 (31)</cell><cell>51 (29)</cell><cell></cell><cell>18 (17)</cell><cell>5 (6.6)</cell></row><row><cell>Disease control rate c</cell><cell>123 (69)</cell><cell>112 (64)</cell><cell>0.7</cell><cell>50 (49)</cell><cell>24</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 3 -</head><label>3</label><figDesc><div><p><s>Safety overview</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>So-Su</cell><cell></cell><cell></cell><cell></cell><cell>Su-So</cell><cell></cell></row><row><cell></cell><cell cols="2">First-line So (n = 177)</cell><cell cols="2">Second-line Su (n = 103)</cell><cell cols="2">First-line Su (n = 176)</cell><cell cols="2">Second-line So (n = 76)</cell></row><row><cell>Mean therapy duration, wk (SD)</cell><cell cols="2">37.5 (37.4) a,b</cell><cell cols="2">28.2 (29.6) c</cell><cell cols="2">43.9 (44.3) b</cell><cell cols="2">16.0 (15.2) c,d</cell></row><row><cell>Dose reductions, n (%)</cell><cell cols="2">65 (37)</cell><cell cols="2">24 (23)</cell><cell cols="2">65 (37)</cell><cell cols="2">35 (46)</cell></row><row><cell>Dose interruptions, n (%)</cell><cell cols="2">81 (46)</cell><cell cols="2">30 (29)</cell><cell cols="2">71 (40)</cell><cell cols="2">26 (34)</cell></row><row><cell>Any TEAE, n (%)</cell><cell cols="2">172 (97)</cell><cell cols="2">90 (87)</cell><cell cols="2">172 (98)</cell><cell cols="2">64 (84)</cell></row><row><cell>Grade 3/4 TEAE, n (%)</cell><cell cols="2">117 (66)</cell><cell cols="2">53 (51)</cell><cell cols="2">118 (67)</cell><cell cols="2">27 (36)</cell></row><row><cell>AEs leading to withdrawal, n (%)</cell><cell cols="2">33 (19) e</cell><cell cols="2">20 (19)</cell><cell cols="2">52 (30) e</cell><cell cols="2">15 (20)</cell></row><row><cell>Any serious AE, n (%)</cell><cell cols="2">88 (50)</cell><cell cols="2">43 (42)</cell><cell cols="2">81 (46)</cell><cell cols="2">19 (25)</cell></row><row><cell>AEs related to deaths, n (%)</cell><cell cols="2">12 (6.7)</cell><cell cols="2">1 (1.0)</cell><cell cols="2">16 (9.1)</cell><cell cols="2">2 (2.6)</cell></row><row><cell>Most frequent TEAEs f , n (%)</cell><cell>All</cell><cell>Grade 3/4</cell><cell>All</cell><cell>Grade 3/4</cell><cell>All</cell><cell>Grade 3/4</cell><cell>All</cell><cell>Grade 3/4</cell></row><row><cell>Diarrhoea</cell><cell>96 (54)</cell><cell>9 (5.1)</cell><cell>16 (16)</cell><cell>2 (1.9)</cell><cell>70 (40)</cell><cell>5 (2.8)</cell><cell>26 (34)</cell><cell>3 (3.9)</cell></row><row><cell>Hand-foot skin reaction</cell><cell>69 (39)</cell><cell>21 (12)</cell><cell>14 (14)</cell><cell>5 (4.9)</cell><cell>38 (22)</cell><cell>10 (5.7)</cell><cell>16 (21)</cell><cell>5 (6.6)</cell></row><row><cell>Hypertension</cell><cell>57 (32)</cell><cell>16 (9.0)</cell><cell>11 (11)</cell><cell>3 (2.9)</cell><cell>58 (33)</cell><cell>21 (12)</cell><cell>6 (7.9)</cell><cell>2 (2.6)</cell></row><row><cell>Fatigue</cell><cell>56 (32)</cell><cell>8 (4.5)</cell><cell>24 (23)</cell><cell>3 (2.9)</cell><cell>70 (40)</cell><cell>13 (7.4)</cell><cell>9 (12)</cell><cell>0</cell></row><row><cell>Alopecia</cell><cell>55 (31)</cell><cell>-</cell><cell>2 (1.9)</cell><cell>-</cell><cell>10 (5.7)</cell><cell>-</cell><cell>4 (5.3)</cell><cell>-</cell></row><row><cell>Rash</cell><cell>48 (27)</cell><cell>3 (1.7)</cell><cell>8 (7.8)</cell><cell>0</cell><cell>10 (5.7)</cell><cell>0</cell><cell>12 (16)</cell><cell>1 (1.3)</cell></row><row><cell>Nausea</cell><cell>39 (22)</cell><cell>2 (1.1)</cell><cell>17 (17)</cell><cell>1 (1.0)</cell><cell>53 (30)</cell><cell>3 (1.7)</cell><cell>6 (7.9)</cell><cell>1 (1.3)</cell></row><row><cell>Loss of appetite</cell><cell>37 (21)</cell><cell>2 (1.1)</cell><cell>16 (16)</cell><cell>2 (1.9)</cell><cell>30 (17)</cell><cell>4 (2.3)</cell><cell>12 (16)</cell><cell>0</cell></row><row><cell>Pain</cell><cell>33 (19)</cell><cell>6 (3.4)</cell><cell>11 (11)</cell><cell>4 (3.9)</cell><cell>25 (14)</cell><cell>4 (2.3)</cell><cell>4 (5.3)</cell><cell>0</cell></row><row><cell>Stomatitis</cell><cell>15 (8.5)</cell><cell>0</cell><cell>9 (8.7)</cell><cell>0</cell><cell>37</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgments: We thank all the patients, caregivers, and investigators who participated in this study; the principal investigators are listed in Supplementary Appendix A. We also thank Emma Robinson and Jenny Handford from 7.4 Limited, who provided medical writing support funded by Bayer HealthCare Pharmaceuticals.</s><s>This manuscript was presented in part at scientific congresses as follows: Oral presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, CA, USA, January 30-February 1, 2014 (abstract 393); poster presentation at the 50th American Society of</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Author contributions: Christian Eichelberg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</s></p><p><s>Financial disclosures: Christian Eichelberg certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Christian Eichelberg has received honoraria from Bayer, Pfizer, Novartis, and GSK; has served as a consultant/advisor for Bayer; and has received research funding from Bayer, Pfizer, and Novartis.</s><s>Maria De Santis has received honoraria from, served as a consultant/advisor for, or served on speakers' bureaus for Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Celgene, Dendreon, Ferring, GSK, Janssen Cilag, Novartis, Pfizer, Pierre-Fabre Oncology, Roche, Sanofi Aventis, Takeda, and Teva/ OncoGenex; and has received research funding from Pierre-Fabre Oncology.</s><s>Peter J. Goebell has received honoraria from, served as a consultant/advisor for, and provided expert testimony for Amgen, Bayer, BMS, GSK, Novartis, Pfizer, Roche, Pierre-Fabre, and Sanofi.</s><s>Michael Staehler has received honoraria from, served as a consultant/ advisor for, served on speakers' bureaus for, or received research funding from Bayer, Pfizer, Roche, Novartis, and GSK.</s><s>Maurice S. Michel has received honoraria from Bayer, Astellas, Novartis, GSK, and Hexal; has served as a consultant/advisor for Bayer, Astellas, Novartis, GSK, and Hexal; has served on speakers' bureaus for Bayer; and has patent or intellectual property interests with Karl Storz.</s><s>The remaining authors have nothing to disclosure.</s><s>Appendix A. Supplementary data Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.</s><s>eururo.2015.04.017.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">Drafting of the manuscript: Michel, Staehler, Eichelberg, de Santis, Goebell. Critical revision of the manuscript for important intellectual content: Eichelberg</title>
		<author>
			<persName><surname>Study</surname></persName>
		</author>
		<author>
			<persName><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><surname>Eichelberg</surname></persName>
		</author>
		<author>
			<persName><surname>De Santis</surname></persName>
		</author>
		<author>
			<persName><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><surname>Eichelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Flo</forename><surname>Fischer Von Weikersthal</surname></persName>
		</author>
		<author>
			<persName><surname>Freier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lerchenmu</forename><surname>Goebell</surname></persName>
		</author>
		<author>
			<persName><surname>¨ller</surname></persName>
		</author>
		<author>
			<persName><surname>Los</surname></persName>
		</author>
		<author>
			<persName><surname>Michel</surname></persName>
		</author>
		<author>
			<persName><surname>Pahernik</surname></persName>
		</author>
		<author>
			<persName><surname>Schenck</surname></persName>
		</author>
		<author>
			<persName><surname>Schirrmacher-Memmel</surname></persName>
		</author>
		<author>
			<persName><surname>Staehler</surname></persName>
		</author>
		<author>
			<persName><surname>Van Arkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Zimmermann</forename><surname>Vervenne</surname></persName>
		</author>
		<imprint>
			<pubPlace>Eichelberg, Gottstein, Hauswald, Indorf; Vervenne, De Santis</pubPlace>
		</imprint>
	</monogr>
	<note>Analysis and interpretation of data: Michel. Fischer von Weikersthal, Goebell, Lerchenmu ¨ller, Zimmermann, Bos, Freier, Schirrmacher-Memmel</note>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<author>
			<persName><forename type="first">Pahernik</forename><surname>Staehler</surname></persName>
		</author>
		<author>
			<persName><surname>Los</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Flo</forename><forename type="middle">¨rcken</forename><surname>Schenck</surname></persName>
		</author>
		<author>
			<persName><surname>Van Arkel</surname></persName>
		</author>
		<author>
			<persName><surname>Hauswald</surname></persName>
		</author>
		<author>
			<persName><surname>Indorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michel</forename><surname>Gottstein</surname></persName>
		</author>
		<title level="m">Statistical analysis: Gottstein. Obtaining funding: Michel</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m">Administrative, technical, or material support: Indorf, Hauswald, Michel. Supervision: Michel. Other: None</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Evolving therapeutic targets in renal cell carcinoma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchalik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Srinivasan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="273" to="280" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Vogelzang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="286" to="296" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement</title>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tortora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Linassier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1896" to="1907" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit</title>
		<author>
			<persName><forename type="first">S</forename><surname>Oudard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Elaidi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="981" to="987" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Mendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Laird</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="327" to="337" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Wilhelm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="7099" to="7109" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Stadler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3312" to="3318" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Esteban</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="760" to="767" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Guidelines on renal cell carcinoma</title>
		<author>
			<persName><forename type="first">B</forename><surname>Ljungberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bensalah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bex</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">European Association of Urology</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nosov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="3791" to="3799" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">I</forename><surname>Rini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomczak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="1931" to="1939" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Buchler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pavlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Bortlicek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3321" to="3324" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter</title>
		<author>
			<persName><forename type="first">N</forename><surname>Calvani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Morelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Leo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1908" to="1913" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Heuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">K</forename><surname>Chun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1373" to="1378" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Procopio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">`g</forename><surname>Cartenı</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BJU Int</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="E250" to="257" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Stenner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chastonay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liewen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="333" to="340" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. Presentation at the German Cancer Congress (DKK)</title>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carteni</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">O119</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bacik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mazumdar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="289" to="296" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Goebell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Vervenne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">835P</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Gschwend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Beeker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Santis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page">S4591</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lesovoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Al-Shukri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1287" to="1294" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomczak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="115" to="124" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Pazopanib versus sunitinib in metastatic renal-cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="722" to="731" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Alimohamed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Srinivas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Genitourin Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="e127" to="131" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Barrios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2765" to="2772" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Filson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Redman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="825" to="830" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Paglino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Imarisio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish registerbased study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ambring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bjorholt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Stierner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="331" to="338" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Escudier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bono</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1412" to="1418" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bhojani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jeldres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Patard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="917" to="930" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title level="m" type="main">Targeted therapies for renal cell carcinoma: review of adverse event management strategies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Sternberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="93" to="113" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">EURURO-6176</title>
	</analytic>
	<monogr>
		<title level="j">No. of Pages</title>
		<imprint>
			<biblScope unit="page">11</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="2432" to="2440" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bellmunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dutcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="311" to="318" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Rupnick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kerlela</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="2011" to="2019" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis</title>
		<author>
			<persName><forename type="first">Di</forename><surname>Lorenzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Autorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bruni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1535" to="1542" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Harshman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Srinivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Witteles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Heart Fail</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="72" to="78" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Confusion of therapeutic approaches</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ivanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Grunwald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dtsch Arztebl Int</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page">405</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Je</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Schutz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3450" to="3456" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Cardiovascular toxicity caused by cancer treatment: strategies for early detection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Altena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>De Vries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Gietema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Perik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="391" to="399" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<monogr>
		<title level="m" type="main">Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Jensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hasbak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mortensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Sorensen</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="5280" to="5286" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC)</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Manola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Role of sorafenib in renal cell carcinoma: focus on elderly patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1689" to="1692" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Sorafenib as first-or secondline therapy in patients with metastatic renal cell carcinoma in a community setting</title>
		<author>
			<persName><forename type="first">G</forename><surname>Procopio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Derosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gernone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1741" to="1750" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Sorafenib and sunitinib for elderly patients with renal cell carcinoma</title>
		<author>
			<persName><forename type="first">O</forename><surname>Derbel Miled</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dionne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Terret</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Geriatr Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="255" to="261" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eichelberg</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2015.04.017</idno>
		<ptr target="http://dx.doi.org/10.1016/j.eururo.2015.04.017" />
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Please cite this article in press as</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
